Rasio rega marang bathi Nuvation Corp (NUVB)

The IFRS P/E ratio reflects the market valuation dynamics of Nuvation Bio Inc. (NUVB), with the latest value recorded as -10.50. Progress in developing anti-cancer agents is being driven by AI-driven molecular design and automation. Substantial cash reserves ensure financial stability until the company becomes a free cash flow generator. Meanwhile, development risks are mitigated through the acquisition of assets currently in the final commercial stages.

Nuvation Pharma (NUVB) - Rasio rega marang bathi saka 04.07.2022 nganti 14.11.2026

Rincian metrik komprehensif lan analitis nuvationbio.com (NUVB)

- rega lan prakiraan konsensus rega:

Rega saham Nuvation Bio Inc|NUVB - Bagan rega target

- rincian kapitalisasi pasar:

Nilai pasar Nuvation Corp|NUVB - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- informasi kapitalisasi buku:

Nilai Akuntansi Saham Nuvation Bio|NUVB - Nilai Buku Perusahaan|Koefisien Nilai Pasar marang Nilai Buku nuvationbio.com|NUVB - Aset Agregat Perusahaan

- statistik kawajiban utang lan likuiditas:

- indikator bathi lan kelipatan valuasi:

NUVB - Bathi resik|Proyeksi bathi resik Nuvation Bio Inc.|NUVB - Koefisien rega marang bathi|Rasio prakiraan rega marang bathi Nuvation Bio Inc.|NUVB - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Nuvation Corp|NUVB - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone patang kuartal pungkasan Nuvation Bio|NUVB - Bathi resik saben saham (EPS TTM)|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan nuvationbio.com|NUVB - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Nuvation Bio Inc.

- indikator volume dodolan lan pendapatan:

NUVB - Pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan Nuvation Bio|NUVB - Multiplikator P/S|Multiplikator Forward P/S Nuvation Pharma

Analisis komprehensif perusahaan:NUVB (Nuvation Bio Inc)

Analyzing the current P/E of Nuvation Bio Inc. (NUVB), investors are assessing the efficiency of integrating new clinical assets through the lens of the market value per unit of profit. This ratio reflects the dynamics of capitalization revaluation relative to actual earnings, allowing for the timely identification of shifts in market sentiment and the protection of capital from drawdowns during the management's structural adaptation period.

Analisis perusahaan pesaing

Pangali P/E Incyte Corp|Koefisien rega marang bathi HCM (HUTCHMED Ltd)|Rasio rega marang bathi DAWN (Day One)|Monopar Therapeutics - Koefisien rega marang bathi|Nilai perusahaan marang bathi resik INBX|IMAB - Rasio rega marang bathi|Kapitalisasi marang bathi Fennec Pharma|Heron Therapeutics (HRTX) - Rasio rega marang bathi|Pangali rega marang bathi NVCT|CHRS (Coherus BioSciences, Inc.) - Pangali P/E|Koefisien rega marang bathi corbuspharma.com (CRBP)|Rasio rega marang bathi Cardiff Oncology, Inc. (CRDF)|BYSI - Kapitalisasi marang bathi|Rasio rega marang bathi BioAtla Corp BCAB|Lixte Biotechnology, Inc. - Rasio rega marang bathi|CTXR - Rasio rega marang bathi|Kapitalisasi marang bathi Cellectar Biosciences|BLRX: Pangali P/E|Rasio kapitalisasi marang bathi resik Can-Fite BioPharma, Ltd. CANF|Koefisien rega marang bathi APRE|Kapitalisasi marang bathi Kazia Therapeutics Limited KZIA|Koefisien rega marang bathi SLXN (Silexion Therapeutics Corp.)|NCNA (NuCana Corp) - Nilai perusahaan marang bathi resik|Chimerix, Inc. - Koefisien rega marang bathi|Rasio rega pasar marang bathi resik CYCC (Cyclacel)|G1 Therapeutics - Pangali P/E|Nilai perusahaan marang bathi resik KRON (Kronos Bio Corp)|KTRA: Pangali P/E|Kapitalisasi marang bathi oncternal.com (ONCT)|Rasio rega marang bathi Portage Biotech